GSK/CNS deal complete
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline has completed its $566 million acquisition of Breathe Right and FiberChoice maker CNS, the firm announces Dec. 19. "The opportunity for growth through geographic expansion make[s] this an exciting prospect," GSK Consumer Healthcare President John Clarke said. FiberChoice is sold only in the U.S., but Breathe Right is sold in 26 countries including Hong Kong, Mexico, South Africa and Portugal, according to GSK. The acquisition should help CNS protect the intellectual property rights and market share of its Breathe Right brand, the firm said in a filing with the Securities & Exchange Commission (1"The Tan Sheet" Nov. 6, 2006, p. 3)...
You may also be interested in...
GSK Launches Breathe Right Kids, Cites Scrutiny Of Pediatric Cold Products
GlaxoSmithKline joins the list of manufacturers launching drug-free cough/cold remedies for children to meet growing demand in the wake of FDA's review of pediatric OTC drugs
GSK Merger Helps CNS Breathe Easier About Breathe Right Patent Expiration
CNS sees its proposed acquisition by Glaxo as an opportunity to protect the intellectual property rights and market share of its Breathe Right brand with the additional resources available to a larger company
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.